Exelixis announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board, or DSMB, unanimously recommended to unblind and stop the phase 3 CABINET pivotal trial early due to an improvement in efficacy that was observed at an interim analysis. CABINET is evaluating cabozantinib compared with placebo in patients with either advanced pancreatic neuroendocrine tumors, or pNET, or advanced extra-pancreatic neuroendocrine tumors (also referred to as carcinoid tumors) who experienced progression after prior systemic therapy. Cabozantinib substantially prolonged the time without disease progression or death in both of the trial’s cohorts. CABINET is sponsored by the National Cancer Institute, or NCI, and is led by The Alliance for Clinical Trials in Oncology. Detailed findings will be presented at an upcoming medical meeting and discussed with the FDA. The safety profile of cabozantinib observed in the trial was consistent with its known safety profile, and no new safety signals were identified.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EXEL:
- Exelixis appoints Amy Peteson as Chief Medical Officer
- Exelixis price target raised to $27 from $24 at JMP Securities
- Exelixis, Ipsen announce CONTACT-02 trial met one of two primary endpoints
- DraftKings upgraded, Home Depot downgraded: Wall Street’s top analyst calls
- SVB Securities starts Exelixis with a Market Perform, $18 price target